Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients

Transplantation

Volumn 72, Issue 6, 2001, Pages 1078-1086

  Savoldo, Barbara ^a   Goss, John ^b   Liu, Zhensheng ^a   Huls, M Helen ^a   Doster, Sheri ^b   Gee, Adrian P ^a   Brenner, Malcolm K ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; TACROLIMUS;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; AUTOTRANSPLANTATION; CELL FUNCTION; CELL TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0035959982     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200109270-00017     Document Type: Article

References (42)

1. The role of immunosuppression in lymphoma formation
2. Epstein-Barr Virus. Biology, pathogenesis and medical aspects
3. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
4. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
5. EBV persistence in memory B cells in vivo
6. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation
7. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients
8. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children
9. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation
10. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
11. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
12. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin
13. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals
14. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients
15. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
16. Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV type A and B
17. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma
18. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
19. Pharmacologic aspects of cyclosporine therapy: Pharmacokinetics
20. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
21. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells
22. The effects of cyclosporin A on the immune system
23. Selective inhibition of immunoregulatory cell functions by cyclosporin A
24. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients
25. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease
26. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease
27. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders
28. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
29. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus
30. Treatment of posttransplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
31. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
32. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
33. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
34. Gamma delta T cell receptor-bearing lymphocytes during Epstein-Barr virus infection
35. V delta 1+ subset of human gamma delta T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B lymphocytes
36. TCR gamma delta cells-minor redundant T cell subset or specialized immune system component?
37. Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction
38. Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells
39. Involvement of FK506-sensitive and insensitive granule exocytosis pathways in perforin-dependent target cell lysis mediated by a CD8+ CTL clone
40. Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry
41. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens
42. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease